Universite Dé Lorraine

National Institute of Health and Medical Research

Inotrem

Assistance Publique - Hopitaux De Paris (Aphp)

Centre Hospitalier Regional Universitaire De Nancy

Sorbonne Université

Universite Paris Cité

Aphp

Inserm

Amir Boufenzer

Marc Derive

Sebastien Gibot

Hafid Ait-Oufella

Nicolas Danchin

Céline Huselstein

Léonore Avercenc

Caroline Laroye

Loïc Reppel

Danièle Bensoussan

Lucie Jolly

Martin Koch

Kevin Carrasco

Aurelie Olivier

Jean-Jacques Garaud

Margarita Salcedo-magguilli

Sébastien Gibot

Tabasomme Simon

The present disclosure relates to a method of treating an acute inflammatory disorder such as septic shock in a subject in need thereof. The method involves administering to a subject who has a soluble TREM-1 (sTREM-1) level measured in a biological sample from the subject greater than a predetermined sTREM-1 value an amount of a TREM-1 inhibitor sufficient to treat the inflammatory disorder.

Method for treating septic shock

The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.

Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis

A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.

Methods and kits for predicting the risk of having a cardiovascular disease or event

The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.

Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases

Growing community of inventors

Nancy, France

Amir Boufenzer